ABSTRACT
Crude CH2Cl2 extract from leaves of Piper laevicarpu (Piperaceae) displayed antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi (Y strain) and antimicrobial potential against Cryptococcus gattii (strain-type WM 178). Bioactivity-guided fractionation of crude extract afforded one new natural bioactive lactam derivative, named laevicarpin. The structure of isolated compound, which displayed a very rare ring system, was elucidated based on NMR, IR and MS spectral analysis. Using MTT assay, the trypomastigotes of T. cruzi demonstrated susceptibility to laevicarpin displaying IC50 value of 14.7µg/mL (49.6µM), about 10-fold more potent than the standard drug benznidazole. The mammalian cytotoxicity of laevicarpin was verified against murine fibroblasts (NCTC cells) and demonstrated a CC50 value of 100.3µg/mL (337.7µM-SI=7). When tested against Cryptococcus gattii, laevicarpin showed an IC50 value of 2.3µg/mL (7.9µM) and a MIC value of 7.4µg/mL (25µM). Based in the obtained results, laevicarpin could be used as a scaffold for future drug design studies against the Chagas disease and anti-cryptococosis agents.
Subject(s)
Antifungal Agents/pharmacology , Lactams/pharmacology , Piper/chemistry , Plant Extracts/pharmacology , Trypanocidal Agents/pharmacology , Animals , Antifungal Agents/isolation & purification , Cell Line , Cryptococcus gattii/drug effects , Inhibitory Concentration 50 , Lactams/chemistry , Lactams/isolation & purification , Mice , Microbial Sensitivity Tests , Molecular Structure , Plant Leaves/chemistry , Trypanocidal Agents/isolation & purification , Trypanosoma cruzi/drug effectsABSTRACT
O enfisema lobar congênito é uma doença na qual as manifestações clínicas, quase sempre, aparecem nos primeiros seis meses de idade. Neste relato, os primeiros sintomas surgiram em uma paciente de 20 anos, quando desenvolveu um pneumotórax espontâneo, acontecimentos esses excepcionais. São revistas as possíveis etiologias dessa malformação congênita pulmonar e são justificadas as razões para a manutenção do tratamento conservador
